top of page
PXT3003 Phase III Results Published: A Milestone for Multimodal Therapy in CMT1A
A published Phase III trial in China met its primary endpoint for PXT3003 in CMT1A, highlighting promising functional outcomes and the pioneering multimodal therapy expertise of Tangramed's scientific leadership.
Sep 18
Tangramed Biotech and Biomunex Pharmaceuticals Announce AI-Driven Research Collaboration
Tangramed Biotech and Biomunex Pharmaceuticals are collaborating to identify and prioritize novel oncology target combinations through AI-enabled drug discovery.
May 26
bottom of page